Genprex, Inc. announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference.
Genprex, Inc. has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program.
Genprex, Inc. announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer.
Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate.
Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients.
A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.
New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL.
A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office.
Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.
Composition of Matter Patent Covers Broad Therapeutic and Diagnostic Applications